LCTX (Lineage Cell Therapeutics) Moat Score: 3/10 (As of Jul. 01, 2026)


LCTX Lineage Cell Therapeutics Inc LCTX
79 GF Score
Price $1.30
GF Value $1.33
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Moat Score?

Lineage Cell Therapeutics LCTX -0.60% 79 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates LCTX with a GF Score™ of 79/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,400 Biotechnology companies, Lineage Cell Therapeutics ranks better than 75.5% on this metric.

Lineage Cell Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Lineage Cell Therapeutics has No Moat: Lineage Cell Therapeutics Inc has some intellectual property in the biotech space, but lacks market leadership and strong customer loyalty. The company faces significant competition and does not have durable cost advantages or regulatory barriers that would provide a sustainable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lineage Cell Therapeutics might have No Moat - Very weak/transient advantages.

Lineage Cell Therapeutics  (AMEX:LCTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lineage Cell Therapeutics Moat Score Related Terms

LCTX vs NWBO, ABEO, VRXA: Moat Score Comparison

For the Biotechnology subindustry, Lineage Cell Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Moat Score falls into.


LCTX
79GF Score
Lineage Cell Therapeutics Inc LCTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Lineage Cell Therapeutics (LCTX) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Lineage Cell Therapeutics ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Lineage Cell Therapeutics' Moat Score too high?
Lineage Cell Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Lineage Cell Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lineage Cell Therapeutics has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Moat Score compare to NWBO and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #343 out of 1400 companies for Moat Score. This places Lineage Cell Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Lineage Cell Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.30 — trading 2.1% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Lineage Cell Therapeutics' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of $1.30 is trading 2.1% below its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

  • Moat Score: 3
  • GF Value™: $1.33 vs. price of $1.30 (2.1% below fair value)
  • GF Score™: 79/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1400)

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:IsraelBT3:Germany
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
79GF Score

Get the complete analysis for LCTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.30
Price
$1.33
GF Value